SeekingAlpha · Aug 13, 2026
LeMaitre Vascular: 31% Drawdown On $0.02 Guidance Cut
LeMaitre Vascular stock remains a Buy after a 31% pullback. Click to see LMAT's Q2 drivers, Artegraft growth, margin upside, and valuation reset.
LM
NASDAQ · LMAT
LeMaitre Vascular, Inc.
Healthcare · Medical - Instruments & Supplies
$79.67
Up+$0.06 (+0.07%)
Updated Aug 28, 2026, 10:48 AM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.89B
- P/E ratio
- 35.4
- Dividend yield
- 1.00%
- 52-week range
- $78.27 – $118.01
- Volume
- 208.76K
- Avg. volume
- 168.66K
Price performance
LMAT price history
1M range · 21 trading sessions · Daily adjusted prices
LMAT closed at $79.67 after 21 trading sessions, down 22.04% for the selected period.
- Last close
- $79.67
- Period change
- -22.04%
- Period low
- $78.97
- Period high
- $105.78
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $79.61 | $79.8752 | $79.0602 | $79.665 | 208.76K |
| Aug 26, 2026 | $78.91 | $79.81 | $78.27 | $79.61 | 150.42K |
| Aug 25, 2026 | $80.24 | $80.77 | $78.285 | $78.97 | 447.67K |
| Aug 24, 2026 | $81.94 | $82.74 | $79.65 | $79.96 | 562K |
| Aug 21, 2026 | $82.37 | $82.875 | $81.6075 | $81.86 | 419.89K |
| Aug 20, 2026 | $83.07 | $83.545 | $81.98 | $82.32 | 269.46K |
| Aug 19, 2026 | $82.15 | $84.115 | $81.57 | $83.87 | 252.04K |
| Aug 18, 2026 | $82.97 | $84.35 | $81.305 | $81.52 | 467.85K |
| Aug 17, 2026 | $81.97 | $82.70 | $81.1125 | $82.51 | 266.66K |
| Aug 14, 2026 | $81.25 | $82.605 | $80.72 | $82.38 | 553.27K |
| Aug 13, 2026 | $82.44 | $82.97 | $81.80 | $81.93 | 304.06K |
| Aug 12, 2026 | $81.96 | $82.185 | $79.945 | $82.13 | 349.91K |
| Aug 11, 2026 | $82.02 | $82.95 | $80.62 | $82.84 | 323.27K |
| Aug 10, 2026 | $80.60 | $83.07 | $79.495 | $81.19 | 468.32K |
| Aug 7, 2026 | $80.69 | $81.83 | $79.40 | $81.45 | 394.8K |
| Aug 6, 2026 | $80.64 | $82.28 | $79.26 | $80.82 | 666.57K |
| Aug 5, 2026 | $88.15 | $90.28 | $78.65 | $79.00 | 2.19M |
| Aug 4, 2026 | $102.75 | $106.19 | $101.66 | $105.78 | 407.88K |
| Aug 3, 2026 | $103.19 | $106.255 | $101.955 | $103.61 | 321.11K |
| Jul 31, 2026 | $101.34 | $102.10 | $99.31 | $101.32 | 234.19K |
| Jul 30, 2026 | $102.52 | $102.6975 | $100.68 | $102.19 | 186.26K |
Latest LMAT news
The latest Smart Investors Daily articles mentioning LMAT.
Stock researchCompany · Overview
LMAT research
Overview
Company profile and research snapshot.
Company profile
LeMaitre Vascular Inc manufactures and distributes medical devices for the treatment of peripheral vascular disease. Its products are used during open vascular surgery and address several anatomical areas, such as the carotid, lower extremities, upper extremities, and aorta. The firm's lower extremities product line contributes towards the proportion of revenue, followed by the carotid product line. LeMaitre's surgical devices include angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches and vessel closure systems.It has a single operating segment engaged in the development, manufacturing, and marketing of medical devices and implants, as well as the processing and cryopreservation of human tissues for implantation in patients.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $101.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 5, 2026 | Wells Fargo | Equal-Weight | — |
| Jun 3, 2026 | Barrington Research | Outperform | — |
| May 6, 2026 | Citizens | Market Outperform | — |
| May 6, 2026 | Barrington Research | Outperform | — |
| May 6, 2026 | Wells Fargo | Equal-Weight | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 5, 2026
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Zhengye Biotechnology (NASDAQ:ZYBT) stock increased by 107.0% to $2.65 during Wednesday's regular session. The company's market cap stands at $60.6 million. Bluejay Diagnostics (NASDAQ:BJDX) shares
Benzinga · Aug 5, 2026
Wells Fargo Maintains Equal-Weight on LeMaitre Vascular, Lowers Price Target to $94
Wells Fargo analyst Nathan Treybeck maintains LeMaitre Vascular (NASDAQ:LMAT) with a Equal-Weight and lowers the price target from $104 to $94.
ChartMill · Aug 5, 2026
LeMaitre Vascular (NASDAQ:LMAT) Shares Slide on Q2 Earnings Miss
LeMaitre Vascular (LMAT) missed Q2 revenue and EPS estimates, sending shares down over 12% after hours despite 9.6% revenue growth.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
